MIP-1α and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis  by Wada, Takashi et al.
Kidney International, Vol. 56 (1999), pp. 995–1003
MIP-1a and MCP-1 contribute to crescents and interstitial
lesions in human crescentic glomerulonephritis
TAKASHI WADA, KENGO FURUICHI, CHIKAKO SEGAWA-TAKAEDA, MIHO SHIMIZU, NORIHIKO
SAKAI, SHIN-ICHI TAKEDA, KAZUYA TAKASAWA, HIROSHI KIDA, KEN-ICHI KOBAYASHI,
NAOFUMI MUKAIDA, YASUKAZU OHMOTO, KOUJI MATSUSHIMA, and HITOSHI YOKOYAMA
First Department of Internal Medicine and Division of Blood Purification, School of Medicine, and Department of Molecular
Pharmacology, Cancer Research Institute, Kanazawa University, and Department of Internal Medicine, Kanazawa National
Hospital, Kanazawa; Kurobe Municipal Hospital, Kurobe; Cell Technology Institute, Ohtsuka Pharmaceutical Company, Ltd.,
Tokushima; and Department of Molecular Preventive Medicine, School of Medicine, The University of Tokyo, Tokyo, Japan
crescents in the acute phase via CCR5 and that MCP-1 mayMIP-1a and MCP-1 contribute to crescents and interstitial
be involved mainly in the development of interstitial lesionslesions in human crescentic glomerulonephritis.
in the chronic phase when fibrocellular/fibrous crescents areBackground. The precise molecular mechanisms of macro-
present, possibly through Mφ recruitment and activation.phage (Mφ) recruitment and activation in crescentic glomerulo-
nephritis remain to be investigated. We hypothesized that lo-
cally produced macrophage inflammatory protein (MIP)-1a
and monocyte chemoattractant protein (MCP)-1 via the che- Crescentic glomerulonephritis is a prominent featuremokine receptors participate in the pathophysiology of human
in rapidly progressive glomerulonephritis (RPGN) be-crescentic glomerulonephritis by recruiting and activating Mφ.
cause it is associated with a comparable degree of tubulo-Methods. We investigated the levels of MIP-1a and MCP-1
by enzyme-linked immunosorbent assay (ELISA) in 20 healthy interstitial lesions [1]. Activated intraglomerular in-
subjects, 20 patients with crescentic glomerulonephritis, and flammatory monocytes/macrophages (Mφ) are presumed
41 control patients with various other renal diseases. The pres- to be involved in the crescentic glomerulonephritis byence of MIP-1a, MCP-1, and the cognate chemokine receptor
secreting inflammatory mediators, such as cytokines andfor MIP-1a, CCR5, in the diseased kidneys was evaluated by
chemokines [2–5]. In addition, the interactions of infil-immunohistochemical and in situ hybridization analyses.
Results. MIP-1a–positive cells were mainly detected in cres- trating Mφ with renal resident cells, including glomerular
centic lesions, whereas MCP-1 was mainly in the interstitium. In epithelial cells, may play a crucial role in the formation
addition, we detected CCR5-positive cells in diseased glomeruli
of crescents via the up-regulation of adhesion moleculesand interstitium. Urinary MIP-1a was detected in crescentic
and matrix formation [6]. Thus, clarifying the detailedglomerulonephritis, even though it was below detectable levels
in healthy subjects and in patients with other renal diseases mechanisms involved in crescentic formation would be
without crescents. Urinary MIP-1a levels in the patients with useful for a better understanding and therapy of cres-
crescentic glomerulonephritis were well correlated with the centic glomerulonephritis. A variety of factors have been
percentage of cellular crescents and the number of CD68-
implicated thus far both in the recruitment of Mφ into thepositive infiltrating cells and CCR5-positive cells in the glomer-
diseased glomeruli and interstitium and their activation.uli. However, urinary MCP-1 levels were well correlated with
the percentage of both total crescents and fibrocellular/fibrous However, the precise molecular mechanism of the re-
crescents and the number of CD68-positive infiltrating cells in cruitment and activation of Mφ in crescentic glomerulo-
the interstitium. Moreover, elevated urinary levels of both nephritis remains to be investigated.MIP-1a and MCP-1 dramatically decreased during glucocorti-
A chemokine, macrophage inflammatory proteincoid therapy-induced convalescence.
(MIP)-1a, was found to be secreted by mononuclear cells,Conclusions. These observations suggest that locally pro-
duced MIP-1a may be involved in the development of cellular neutrophils, and various nonleukocytic cells, including
inflammatory fibroblasts, astrocytes, and mesangial cells
[7–11]. Recent studies indicate that MIP-1a is involvedKey words: macrophage inflammatory protein-1a, monocyte chemoat-
in the pathogenesis of experimental autoimmune enceph-tractant protein-1, cellular crescents, rapidly progressive glomerulone-
phritis, CCR5. alomyelitis through Mφ recruitment and activation [12].
Moreover, MIP-1a involvement has been demonstratedReceived for publication December 7, 1998
in the pathogenesis of experimental crescentic glomeru-and in revised form March 30, 1999
Accepted for publication April 5, 1999 lonephritis models in vivo [13–15]. Furthermore, recent
studies revealed that the infiltration and activation of 1999 by the International Society of Nephrology
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Table 1. Patient demographics
Urinary levels
Crescents % pg/mg·creatinine CD68 positive cells
No. of patients Age
Diagnosis (male:female) (mean years) Total Cellular MIP-1a MCP-1 /glom /field (3 200)
Healthy subjects 20 (10:10) 16–82 (57.1) ND ND 0 1.060.1 ND ND
Crescentic glomerulonephritis 20 (12:8) 19–82 (56.5) 74.4 65.4a 26.267.0a 4.262.2a 27.366.5a 8.461.8a 39.867.5a
ANCA-related 11 (6:5) 22–77 (61.6) 79.1 66.1 15.365.1 5.963.9 29.368.7 8.064.1 26.768.4
IgA nephropathy 6 (5:1) 19–75 (48.0) 64.0 612.7 18.3610.0 2.662.6 16.564.0 3.460.8 33.4613.1
Lupus nephritis 2 (1:1) 27–74 (55.5) 80.0 614.1 8.065.6 1.161.5 60.6642.7 11.464.8 75.0651.0
Cryoglobulinemia 1 (0:1) 82 70.0 70.0 2.4 6.3 14.0 19.5
Disease controls (without
crescents) 41 (17:24) 16–72 (42.9) 0 0 0.460.2 11.663.5 4.960.7 19.463.9
IgA nephropathy 16 (10:5) 16–72 (50.0) 0 0 0.460.4 4.561.0 2.060.7 12.566.4
Lupus nephritis 18 (3:15) 22–59 (38.5) 0 0 0.560.4 14.065.7 4.861.4 22.068.5
Cryoglobulinimia 1 (1:0) 59 0 0 0 45.7 17.0 45.0
Minimal change nephrotic
syndrome 6 (3:3) 17–60 (30.0) 0 0 0 1.660.4 ND ND
Total 81 (39:42) 16–82 (49.9)
Abbreviations are: ANCA, anti-neutrophilic cytoplasmic antibody; ND, not done; glom, glomerulus; MIP-1a, macrophage inflammatory protein-1a; MCP-1,
monocyte chemoattractant protein-1. Values are mean 6 standard error of the mean.
a P , 0.05 vs. disease controls
leukocytes by MIP-1a is mediated by its cognate chemo- ber 1998 at Kanazawa University Hospital or its affiliate
hospitals. All diagnoses were verified by renal biopsy.kine receptor, CCR5, which is expressed on the target
cells [16, 17]. As previously reported, another chemo- Urinary tract infections were ruled out in all cases by
means of bacterial cultures, microscopic findings, orkine, monocyte chemoattractant protein (MCP)-1, plays
an important role in the pathogenesis of experimental both, because urinary tract infection is associated with
increased urinary MIP-1a and MCP-1 levels (data notglomerulonephritis models [2, 13, 14] and human nephri-
tis [4, 18]. However, the distinct roles of MIP-1a and shown). Whenever possible, patients did not receive im-
munosuppressive agents before the sample collection.MCP-1 via chemokine receptors in the pathogenesis of
human crescentic glomerulonephritis have not yet been All patients who were in a clinically active state were
treated with glucocorticoids, including methylpredniso-investigated.
To determine if locally produced MIP-1a and MCP-1 lone pulse therapy (500 to 1000 mg/day for 3 days), dur-
ing this study. Specimens from second biopsies wereparticipate in the pathophysiology of human crescentic
glomerulonephritis by Mφ recruitment and activation via obtained from six patients with crescentic glomerulone-
phritis after glucocorticoid therapy. All renal biopsiesthe cognate chemokine receptor of MIP-1a, CCR5, we
determined the urinary levels of both MIP-1a and MCP-1 were performed with the consent of the patients.
in patients with crescentic glomerulonephritis and inves-
Pathological studiestigated the relationship between MCP-1, MIP-1a levels
and disease activities, phases of crescentic glomerulone- Sixty-one kidney specimens were obtained by renal
biopsy. Two observers who had no knowledge of thephritis and the chemokine receptor, CCR5.
clinical course of the patients examined the renal tissue
under light microscopy to establish the diagnosis by stan-
METHODS
dard pathological methods. For patients with lupus ne-
Patients phritis, the World Health Organization (WHO) criteria
were used for the light microscopic classification of theTwenty healthy subjects and 61 patients (39 males and
42 females; median age, 49.9 years; range, 16 to 82 years) major forms and the active lesions of the disease [20, 21].
The percentage of the extracapillary lesions, includingwith primary or secondary glomerular diseases were
evaluated in this study (Table 1). Twenty patients had crescentic formation, adhesion, or both, also was counted.
crescentic glomerulonephritis with more than 50% of
Macrophage inflammatory protein-1a and monocytethe total crescents (cellular, fibrocellular, and fibrous) of
chemoattractant protein-1 measurementsall glomeruli showing RPGN clinically [19]; 41 patients
with IgA nephropathy, lupus nephritis, cryoglobulinemia, Spontaneously voided midstream urine catches were
collected on the morning of renal biopsy. Ten millilitersor minimal change nephrotic syndrome served as disease
controls without crescents. Patients with minimal change of the each urine specimen were spun at 200 3 g for
five minutes at room temperature to remove cells andnephrotic syndrome had massive urinary protein excre-
tion (more than 3.5 g/day). The patients in this study precipitates. Serum samples were obtained from patients
at the same time. The urinary supernatants and sera werewere chosen consecutively from August 1992 to Novem-
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kept frozen at 2708C until measurement. Urinary MIP-1a (3200). Two independent observers also examined the
immunohistochemical findings without prior knowledgeand MCP-1 levels were determined by an enzyme-linked
immunosorbent assay (ELISA), using a specific murine of chemokine levels and the clinical courses.
monoclonal antihuman MIP-1a antibody (clone LD78)
In situ hybridization for MIP-1a and MCP-1or monoclonal antihuman MCP-1 antibody (clone ME
69) as a capture and a rabbit polyclonal antibody (either In situ hybridization procedures were the same as
those previously described [23]. A partial sequence ofanti–MIP-1a or anti–MCP-1) as the second antibody as
previously described [22]. These systems are highly spe- exon 1 (59-TCCCTCCTCACCCCCAGATTCCATTTC
CCCATCCGC-39) [24] and a partial sequence of mRNAcific for each MIP-1a or MCP-1, because there were
no cross-reactivities with other chemokines, including (59-CAGAGACTTTCATGCTGGAGGCGAGACTG
CGAGCTT-39) [25] were used for the MIP-1a or MCP-1interleukin (IL)-8, platelet basic protein, platelet factor
4, RANTES (regulated on activation, normal T cell ex- antisense oligonucleotide probe, respectively.
Signals were visualized by using a commercially avail-pression, and secreted), and growth-related gene. The
recovery rate was confirmed to be more than 95% up able digoxigenin-alkaline phosphatase system (DIG Oli-
gonucleotide Tailing kit and Nucleic Acid Detection kit;to 3 ng/ml in these ELISA systems. The possible in vitro
generation of MIP-1a and MCP-1 in urine samples con- Boehringer Mannheim Biochemica, Mannheim, Ger-
many). Negative controls were performed by replacingtaining cells could be excluded by immediate separation
of urinary supernatants by centrifugation. All assays the antisense probe with a sense probe for MIP-1a or
MCP-1, which was the exact complement of the antisensewere performed in duplicate. The detection limits of this
ELISA system were 66 pg/ml for human MIP-1a and 40 probe (59-GCGGATGGGGAAATGGAATCTGGGG
GTGAGGAGGGA-39 or 59-AAGCTCGCACTCTCGpg/ml for human MCP-1. Urinary MIP-1a and MCP-1
levels were standardized by the amount of creatinine in CCTCCAGCATGAAAGTCTCTG-39, respectively).
the urine.
Detection of antineutrophilic cytoplasmic antibody
by ELISAImmunohistochemical studies
The presence of MIP-1a and MCP-1 proteins was Antineutrophilic cytoplasmic antibody (ANCA) was
detected by ELISA using microtiter plates coated withdemonstrated immunohistochemically on frozen tissue
specimens by the indirect avidin-biotinylated alkaline myeloperoxidase extracts for P-ANCA or proteinase-3
for C-ANCA (SRL Co., Tokyo, Japan) [26].phosphatase complex method with either a specific mu-
rine monoclonal antihuman MIP-1a antibody (LD78) or
Statisticsa specific murine monoclonal antihuman MCP-1 anti-
body (ME 69) as previously described [4]. Normal mouse Statistical significance was analyzed using the paired
or unpaired Student’s t-test, analysis of variance test,IgG1, which had been absorbed with both human liver
extracts and immunoglobulin, was used as a negative Spearman’s and Pearson’s correlation coefficient for the
analyses of nonparametric and parametric data, and lo-control. In addition, the absorption test was performed
using a monoclonal antihuman MIP-1a or MCP-1 anti- gistic regression model. P , 0.05 was considered to be
statistically significant.body with excess recombinant MIP-1a or MCP-1 as a
negative control. Furthermore, to determine the localiza-
tion of the cognate receptor of MIP-1a, CCR5, in the
RESULTS
tissue, we demonstrated the presence of CCR5 immuno-
MIP-1a and MCP-1 levels inhistochemically on paraffin-embedded sections by the
crescentic glomerulonephritisindirect avidin-biotinylated alkaline phosphatase com-
plex method with either a specific murine monoclonal Macrophage inflammatory protein-1a was detected in
the urine in 11 of 20 patients with crescentic glomerulo-antihuman CCR5 antibody (clone 2D7; PharMingen, San
Diego, CA, USA) as described earlier here. CD68-posi- nephritis (4.2 6 2.2 pg/mg · creatinine, mean 6 sem;
Table 1 and Fig. 1). In contrast, we did not detect urinarytive cells were detected immunohistochemically on for-
malin-fixed, paraffin-embedded tissue sections treated MIP-1a in patients without crescentic formation or healthy
subjects except for two patients (0.4 6 0.2 pg/mg · creati-by proteinase K for five to six minutes at room tempera-
ture using murine antihuman macrophage CD68 mono- nine, P , 0.01). Two patients with elevated urinary
MIP-1a without crescentic glomerulonephritis had hyper-clonal antibody (clone KP1; Dako, Glostrup, Denmark).
Glomerular chemokine receptor-positive cells and Mφ cellularity of Mφ in glomeruli (19.2 per glomerulus in
lupus nephritis patient and 4.8 per glomerulus in IgAwere expressed as the number of positive cells per glo-
merulus, and mean interstitial chemokine receptor-posi- nephropathy patient) and the interstitium (9.3 per field
in lupus nephritis patient and 44.0 per field in IgA ne-tive cells and Mφ were counted from more than 10 ran-
domly chosen fields under high-power magnification phropathy patient) as revealed by the increased number
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Fig. 1. Urinary macrophage inflammatory
protein-1a (MIP-1a) levels in patients with
various renal diseases. Symbols are: (s) pa-
tients with crescentic glomerulonephritis; (d)
patients without crescentic formation. Abbre-
viations are: MCNS, minimal change ne-
phrotic syndrome; ANCA, antineutrophil cy-
toplasmic antibody.
Table 2. Correlation with urinary levels of MIP-1a and MCP-1 and odds ratio (OR) for the presence of cellular crescents
histological findings in crescentic glomerulonephritis [.10% out of all glomeruli; OR, 17.5 (CI, 0.15 to 0.34);
Urinary MIP-1a Urinary MCP-1 P 5 0.0015). In contrast, there was a significant correla-
tion between the levels of urinary MCP-1 and the per-Pathological findings r P r P
centage of total crescents and fibrocellular and/or fibrousGlomerulus
Total crescent 0.44 NS 0.48 ,0.05 crescents (r 5 0.48, P , 0.05, r 5 0.44, P 5 0.05, respec-
Cellular 0.81 ,0.0001 20.07 NS tively; Table 2). In addition, urinary MCP-1 levels corre-
Fibrocellular/fibrous 20.41 NS 0.44 0.05 lated well with the number of CD68-positive cells in theCD68-positive cells 0.85 ,0.0001 0.30 NS
interstitium in patients with crescentic glomerulonephri-Interstitium
CD68-positive cells 0.12 NS 0.75 ,0.005 tis (r 5 0.75, P , 0.005, N 5 20; Table 2). However, there
Cell infiltration 0.42 NS 0.28 NS was no significant correlation between urinary levels ofFibrosis 20.33 NS 20.02 NS
MIP-1a and MCP-1 in individual patients with crescenticTubular atrophy 20.19 NS 0.06 NS
glomerulonephritis.Abbreviations are: NS, not significant; MIP-1a, macrophage inflammatory
protein-1a; MCP-1, monocyte chemoattractant protein-1.
Urinary MIP-1a levels in lupus nephritis
In 20 patients with lupus nephritis who underwent
renal biopsies, the glomerular appearance was classified
of CD68-positive cells. In addition, serum MIP-1a levels as pure mesangial alteration (WHO II) in 1, focal prolif-
from normal subjects and all patients fell below the de- erative lupus nephritis (PLN, WHO Class III) in 4, dif-
tection limit of ELISA. Similarly, MCP-1 was elevated fuse proliferative lupus nephritis (DPLN, WHO Class
in urine samples in crescentic glomerulonephritis com- IV) in 12, and membranous lupus nephritis (MLN, WHO
pared with urine samples from patients with other renal V) in 3. All patients with the elevated urinary levels of
diseases (27.3 6 6.5, 11.6 6 3.5 pg/mg · creatinine, respec- MIP-1a had DPLN (2 out of 12, 16.6%), whereas urinary
tively, P , 0.05; Table 1). MIP-1a was not detected in any patients with other forms
of lupus nephritis. The activity index ranged from 1 to
Correlation of urinary MIP-1a and MCP-1 levels and 23 (mean 8.0 6 1.9, N 5 20), and two patients with
histological findings DPLN with elevated urinary MIP-1a levels had a higher
Urinary MIP-1a correlated well with the percentage activity index (10 and 18, respectively).
of cellular crescents (r 5 0.81, P , 0.0001, N 5 20)
Immunohistochemical detection of MIP-1a andand the number of CD68-positive cells in glomeruli in
MCP-1 proteins in renal tissuespatients with crescentic glomerulonephritis (r 5 0.85, P ,
0.0001, N 5 20; Table 2). In the logistical analysis, urinary To determine the local production of MIP-1a and
MCP-1, renal tissue from 20 patients with crescentic glo-MIP-1a levels (.0.15 pg/mg · creatinine) showed a high
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merulonephritis was examined immunohistochemically collection. Elevated urinary MIP-1a and MCP-1 levels
significantly decreased during convalescence induced byfor antigenic MIP-1a and MCP-1. MIP-1a–positive cells
were observed in 20 patients with a similar pattern found glucocorticoid therapy alone or with methylprednisolone
pulse therapy in patients examined (MIP-1a, 4.2 6 2.2mainly in the cellular crescents, but also in cortical tubuli,
peritubular capillary endothelial cells, infiltrated mono- vs. 0.1 6 0.1 pg/mg · creatinine, P , 0.01; MCP-1, 27.3 6
6.5 vs. 12.2 6 3.1 pg/mg · creatinine, P , 0.05; Fig. 5). Innuclear cells, and the interstitium (Fig. 2A). However,
MIP-1a was faintly immunohistochemically detected in addition, six patients with crescentic glomerulonephritis
who underwent a second biopsy had fewer cellular cres-tubular epithelial cells in the kidneys from patients of
other renal diseases. In addition, MCP-1–positive cells cents (27.1 6 5.3 vs. 2.1 6 2.1%, P , 0.01) in accordance
with the decrease in MIP-1a urinary levels (4.3 6 3.7 vs.were detected in cortical tubuli, peritubular capillary
endothelial cells, and infiltrated mononuclear cells in the 0.2 6 0.1 pg/mg · creatinine, P , 0.01; Fig. 6).
interstitium in patients with crescentic glomerulonephri-
tis (Fig. 2B). The staining was specific to MIP-1a and
DISCUSSION
MCP-1, because neither the control isotype-matched
This study demonstrated that urinary MIP-1a andmurine IgG nor antibody absorbed with recombinant
MCP-1 levels are elevated in crescentic glomerulone-MIP-1a or MCP-1 stained positively (data not shown).
phritis compared with patients with other renal diseases
or healthy subjects. Patients with minimal change ne-Expression of MIP-1a and MCP-1 transcripts in
renal tissues phrotic syndrome and membraneous lupus nephritis
(MLN) had undetectable levels of urinary MIP-1a orIn situ hybridization detected MIP-1a mRNA signals
MCP-1, similar to those of healthy subjects. These resultsmainly in crescentic lesions and in cortical tubuli, peritu-
suggest that there might be no correlation between levelsbular capillary endothelial cells, infiltrated mononuclear
of urinary MIP-1a and/or MCP-1 and proteinuria causedcells in the glomeruli and the interstitium in the same
by noninflammatory glomerular capillary lesions, suchmanner as the immunohistochemical analyses (Fig. 3A).
as minimal change nephrotic syndrome. Moreover, inIn contrast, MCP-1 mRNA was detected mainly in corti-
the logistical analysis, urinary MIP-1a levels (.0.15 pg/cal tubuli, peritubular capillary endothelial cells, and in-
mg · creatinine) had a high odds ratio for cellular cres-filtrated mononuclear cells in the interstitium, but it was
cents. In contrast, MCP-1 levels correlated with the de-not detected in the glomeruli (Fig. 3 B, C). These stain-
gree of Mφ infiltration in the interstitium showing fibro-ings were specific, because positive staining was not de-
cellular and/or fibrous crescents. Furthermore, there wastected when the tissues were hybridized with the sense
no correlation between urinary levels of MIP-1a andoligonucleotide probe for MIP-1a or MCP-1 (data not
MCP-1 in individual patients with crescentic glomerulo-shown).
nephritis. Thus, we suggest that MIP-1a and MCP-1 may
Localization of CCR5 and correlation between CCR5 have distinct roles in the pathogenesis of different lesions
expression and urinary MIP-1a and phases in crescentic glomerulonephritis. MIP-1a
may specifically promote and escalate Mφ infiltrationTo determine the localization of CCR5, renal tissue
into the glomeruli in the acute process leading to thefrom 20 patients with crescentic glomerulonephritis was
formation of cellular crescents, whereas MCP-1 may par-examined immunohistochemically. CCR5-positive cells
ticipate mainly in the formation of tubulointerstitial le-were observed in both glomeruli and the interstitium in
sions in the chronic phase, which is characterized by the20 patients in a similar pattern (Fig. 4). The number of
formation of fibrocellular and/or fibrous crescents.CCR5-positive cells in both glomeruli and interstitium
In the present study, immunohistochemical analyseswas significantly higher in patients with crescentic glo-
confirmed that immunoreactive MIP-1a–positive cellsmerulonephritis than those of the patients with other
were found mainly in the diseased glomeruli and MCP-1–renal diseases without crescents (0.3 6 0.1 vs. 0.04 6
positive cells mainly in the interstitium. Furthermore,0.02 per glomerulus P , 0.05; 3.5 6 1.1 vs. 1.0 6 0.4 per
in situ hybridization revealed that MIP-1a and MCP-1field of interstitium, P , 0.05). In addition, urinary MIP-1a
mRNA were detected in a similar pattern. Collectively,correlated well with the number of CCR5-positive cells
these chemokines are produced locally in the distinctin glomeruli in patients with crescentic glomerulonephri-
lesions of crescentic glomerulonephritis. In addition,tis (r 5 0.80, P , 0.001, N 5 20), but not correlated with
positive cells for CCR5, the cognate receptor for MIP-1a,those in interstitium (r 5 0.02, N 5 20).
were immunohistochemically detected in the diseased
Effects of glucocorticoid therapy on urinary MIP-1a kidneys. Regarding glomerular lesions, the percentage
and MCP-1 levels of cellular crescents, the number of CD68-positive Mφ
and glomerular CCR5-positive cells correlated with uri-Twenty patients with clinically active crescentic glomer-
ulonephritis received glucocorticoid therapy after sample nary MIP-1a levels, whereas the percentage of fibrocel-
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Fig. 3. In situ hybridization. By in situ hybridization, MIP-1a mRNA
signals were detected mainly in crescentic lesions and in cortical tubuli,
peritubular capillary endothelial cells, infiltrated mononuclear cells in
the glomeruli, and the interstitium in the same manner as the immuno-
histochemical analyses (A). In contrast, MCP-1 mRNA (arrowheads)
was detected mainly in cortical tubuli, peritubular capillary endothelial Fig. 4. Detection of cognate chemokine receptor-5 (CCR5)-positive
cells, and infiltrated mononuclear cells in the interstitium, but was not cells in the tissue. CCR5-positive cells were detected in glomeruli and
detected in the glomeruli (B and C). The sections were observed under interstitium in a representative patient with crescentic glomerulonephri-
light microscopy (A–C, 3320). tis (3320).
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Fig. 2. Immunohistochemical examination. Expression of macrophage inflammatory protein-1a (MIP-1a) or monocyte chemoattractant protein-1
(MCP-1) in renal tissues was detected using a specific monoclonal antihuman MIP-1a or MCP-1 antibody as described in the Methods section.
The sections were observed under light microscopy (A and B, 3320). A representative result from one patient with ANCA-related crescentic
glomerulonephritis is shown. MIP-1a–positive cells were detected mainly in crescents of glomerulus, and tubular epithelial cells and infiltrates in
the interstitium (A). However, MCP-1–positive cells were observed mainly in the endothelial cells, tubular epithelial cells, and infiltrated cells in
the interstitium (B).
b
Fig. 5. Alteration of urinary MIP-1a (A) and
MCP-1 (B) levels following glucocorticoid
therapy in 20 patients with crescentic glomeru-
lonephritis.
Fig. 6. Alteration of urinary MIP-1a levels
(A) and the percentage of cellular crescents
(B) at the first and second renal biopsies fol-
lowing glucocorticoid therapy, including meth-
ylprednisolone pulse therapy in six patients
who underwent a second biopsy.
lular and fibrous crescents correlated with MCP-1 levels. superoxide anions from Mφ in addition to being a chemo-
attractant for Mφ [9, 12]. The involvement of lysosomalMoreover, six patients who underwent a second biopsy
had decreased percentage of cellular crescents in accor- enzymes, nitrous oxide (NO), and reactive oxygen inter-
mediates (ROI) from Mφ has been reported to play andance with decreased MIP-1a levels. Thus far, CCR5 is
thought to be expressed on Mφ and T cells [16]. We essential role in inducing injury in renal tissue [27, 28].
Thus, it is tempting to speculate that MIP-1a may playdetermined that the cell phenotypes of the CCR5-posi-
tive cells in the kidneys are also CD3-positive T cells a crucial role in the pathogenesis of cellular crescents of
crescentic glomerulonephritis by recruiting CCR5-posi-and Mφ (our preliminary data). Taken together, it would
be reasonable to speculate that MIP-1a may participate tive Mφ and T cells, which, in turn, release lysosomal
enzymes, NO, or ROI to induce crescentic formation.more specifically in the acute phases of glomerular lesion
development during the formation of cellular crescents, The expression of MIP-1a and MCP-1 was also up-
regulated in the interstitium, as well as tubular epithelialand that the existence of chemokine receptor can confirm
the functional role of MIP-1a in mediating CCR5-depen- cells, endothelial cells, and mononuclear infiltrates. Pro-
gressive glomerulonephritis, including crescentic glomeru-dent chemotaxis in glomerular lesions in patients with
crescentic glomerulonephritis. MIP-1a has been shown lonephritis, has been reported to be associated with tubu-
lointerstitial involvement [29]. In addition, some studiesto induce the release of lysosomal enzymes and generate
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reported a strict correlation between tubular atrophy, In fact, urinary levels of MIP-1a and MCP-1 fell during
convalescence induced by glucocorticoids, includinginterstitial fibrosis, the extent of interstitial infiltrates,
methylprednisolone pulse therapy. The efficacy of pulseand the renal dysfunction [5]. We previously reported
therapy with glucocorticoids has been established for thethat MCP-1 plays a pivotal role in the tubulointerstitial
treatment of lupus nephritis [34], IgA nephropathy [35],damage and promotes renal dysfunction in human lupus
cryoglobulinemia [36] and RPGN [37], based on im-nephritis [4], IgA nephropathy [18], and an experimental
proved prognoses. Although the precise mechanism of
glomerulonephritis model [2]. In support of this, cyto- the effects of glucocorticoids on renal injury remains to
kines diffuse from hilar areas of the glomeruli or the be investigated, one plausible mechanism may be inhibi-
interstitium and affect tubular cell activation by releasing tion of chemokines, including MCP-1 and MIP-1a. Little
chemokines and fibrogenic factors, such as RANTES is known about the suppressors of MIP-1a production.
[30], osteopontin [31], and MCP-1 [15, 18, 32]. In addi- Neither the glucocorticoid response element nor nuclear
factor-kB (NF-kB) was identified in the 59-flanking re-tion, urinary MCP-1 levels correlated well with the
gion of the MIP-1a gene [38]. A recent study revealedCD68-positive cells in the interstitium, whereas MIP-1a
that glucocorticoids inhibit MCP-1 production at thedid not. This suggests that MCP-1 may be a more impor-
transcriptional level in a human fibrosarcoma cell linetant factor of the progression of tubulointerstitial lesions
[39], but the 59-flanking region of MCP-1 gene containsthan MIP-1a. In addition, CCR5-positive cells were de-
no glucocorticoid response element up to 500 bp. It is
tected in interstitium as well as in glomeruli. However, not clear how glucocorticoids act on mesangial cells,
urinary levels of MIP-1a did not correlate with the num- epithelial cells, or Mφ to inhibit MIP-1a and MCP-1
ber of CCR5-positive cells in the interstitium, suggesting production and cause the resolution of renal diseases.
that another chemotactic factor(s) may be responsible Because glucocorticoids decrease the level of interferon
for the induction of CCR5-positive cells in the intersti- (IFN)-g and tumor necrosis factor (TNF)-a, the inducers
tium, and that CCR5-positive cells may play an impor- of MIP-1a and MCP-1 [11], via inhibition of activity of
NF-kB [40], glucocorticoids might suppress these cyto-tant role in the pathogenesis of both glomerular and, in
kines, thereby inhibiting MIP-1a and MCP-1 production.part, interstitial lesions in crescentic glomerulonephritis.
In addition, recent studies revealed that specific neutral-In contrast, the cognate receptor for MCP-1, CCR2, has
ization of chemokines (MCP-1, MIP-1a) prevented pro-been reported to mediate MCP-1–dependent chemotaxis
teinuria and renal dysfunction in experimental crescenticand activation of target cells [16]. However, the mecha-
glomerulonephritis models [2, 15]. If this is the case,
nism of CCR2-mediated cell infiltration and activation in agents that specifically inhibit MIP-1a and/or MCP-1
renal diseases, including crescentic glomerulonephritis, production or block their biological functions might be
remains to be investigated. Therefore, we believe that replaced in the future with glucocorticoids.
the functional role of MCP-1 via CCR2-dependent che- In summary, our results suggest that MIP-1a and
motaxis in renal diseases should be evaluated in the MCP-1 may be specifically involved in the pathogenesis
of different phases of crescents and distinct diseasedfuture. Alternatively, massive proteinuria might induce
lesions via Mφ recruitment and activation through thetubular epithelial cells to activate lysosome and antigen
cognate chemokine receptor-dependent mechanism andpresentation followed by the activation of helper T cells
that the measurement of urinary MIP-1a and MCP-1in the interstitium [33]. However, at least concerning
levels may be useful for monitoring the different diseaseMIP-1a and MCP-1, proteinuria itself did not induce up-
phases and activities of crescentic glomerulonephritis.
regulation of these chemokines because patients with
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